*/
Patent – Medicine. The Chancery Division made declarations as sought by the claimant pharmaceutical companies. It held that the initial marketing authorisation for a drug, Ribomustin, had been obtained in 2005, as contended by the claimants, rather than 2010, as contended by the defendant pharmaceutical companies. As a result, the ten-year period of delay before the claimants could market their own product had commenced in 2005, not 2010.
Patent – Medicine. The Chancery Division made declarations as sought by the claimant pharmaceutical companies. It held that the initial marketing authorisation for a drug, Ribomustin, had been obtained in 2005, as contended by the claimants, rather than 2010, as contended by the defendant pharmaceutical companies. As a result, the ten-year period of delay before the claimants could market their own product had commenced in 2005, not 2010.
Chair of the Bar Sam Townend KC highlights some of the key achievements at the Bar Council this year
Louise Crush of Westgate Wealth Management highlights some of the ways you can cut your IHT bill
Rachel Davenport breaks down everything you need to know about AlphaBiolabs’ industry-leading laboratory testing services for legal matters
By Louise Crush of Westgate Wealth Management sets out the key steps to your dream property
A centre of excellence for youth justice, the Youth Justice Legal Centre provides specialist training, an advice line and a membership programme
By Kem Kemal of Henry Dannell
Mark Neale, Director General of the Bar Standards Board, offers an update on the Equality Rules consultation
Joanna Hardy-Susskind speaks to those walking away from the criminal Bar
Imposing a professional obligation to act in a way that advances equality, diversity and inclusion is the wrong way to achieve this ambition, says Nick Vineall KC
Tom Cosgrove KC looks at the government’s radical planning reform and the opportunities and challenges ahead for practitioners
By Ashley Friday of AlphaBiolabs
